A new analysis has found that genetic alterations in a particular cellular pathway are linked with bladder cancer risk, recurrence, disease progression, and patient survival. Published early online in CANCER, a peer- reviewed journal of the American Cancer Society, the findings could help improve bladder cancer screening and treatment.
Alterations in the regulators of G-protein signaling (RGS) pathway, which is important for various cellular processes, have been implicated in several cancers. Eugene Lee, MD, of the MD Anderson Cancer Center in Houston, and his colleagues sought to determine the role of RGS alterations in bladder cancer risk, recurrence, disease progression, and patient survival. Dr. Lee is currently a fellow of Dr. Ashish M. Kamat. The researchers worked together with Dr. Xifeng Wu's Epidemiology Lab. They studied 803 patients with non-muscle invasive or muscle invasive bladder cancer and 803 healthy individuals.
After evaluating 95 single nucleotide alterations or variants in 17 RGS genes, the investigators identified several that were linked with overall risk of bladder cancer. The strongest association was seen with the rs10759 variant on the RGS4 gene: it was linked with a 0.77-fold reduced risk of overall bladder cancer. The researchers also found that with an increasing number of unfavorable variants, the risk of bladder cancer increased. "Screening for bladder cancer has proven to be difficult on a population level, and our work may be a first step in identifying molecular markers for potential genetic-based screening tests. This will help recognize specific groups at increased risk beyond the existing known risk factors such as smoking and chemical exposure," said Dr. Lee.
Dr. Lee and his team also revealed that in patients with non-muscle invasive bladder cancer, 11 variants were linked with recurrence and 13 variants were linked with progression. Ten were associated with earlier death in patients with muscle invasive bladder cancer; rs2344673 was the most significant, with an average survival of 13.3 months in patients with the variant compared with 81.9 months in patients without it.
In the current era of personalized medicine, an individual's genetic information can provide valuable information on screening, treatment, and surveillance. "Our study provides an initial step in how we can use a patient's genetic makeup to identify those at risk for bladder cancer. Furthermore, we can identify patients who already have a diagnosis of bladder cancer that are at increased risk of worsening of disease or dying from their cancer," said Dr. Lee. "The goal is to find as many genetic alterations that confer risk and create a panel of markers that would aid in diagnosis, treatment, and follow- up."
###
URL Upon publication: http://doi.wiley.com/10.1002/cncr.27871
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Genetic alterations linked with bladder cancer risk, recurrence, progression, and patient survivalPublic release date: 25-Mar-2013 [ | E-mail | Share ]
A new analysis has found that genetic alterations in a particular cellular pathway are linked with bladder cancer risk, recurrence, disease progression, and patient survival. Published early online in CANCER, a peer- reviewed journal of the American Cancer Society, the findings could help improve bladder cancer screening and treatment.
Alterations in the regulators of G-protein signaling (RGS) pathway, which is important for various cellular processes, have been implicated in several cancers. Eugene Lee, MD, of the MD Anderson Cancer Center in Houston, and his colleagues sought to determine the role of RGS alterations in bladder cancer risk, recurrence, disease progression, and patient survival. Dr. Lee is currently a fellow of Dr. Ashish M. Kamat. The researchers worked together with Dr. Xifeng Wu's Epidemiology Lab. They studied 803 patients with non-muscle invasive or muscle invasive bladder cancer and 803 healthy individuals.
After evaluating 95 single nucleotide alterations or variants in 17 RGS genes, the investigators identified several that were linked with overall risk of bladder cancer. The strongest association was seen with the rs10759 variant on the RGS4 gene: it was linked with a 0.77-fold reduced risk of overall bladder cancer. The researchers also found that with an increasing number of unfavorable variants, the risk of bladder cancer increased. "Screening for bladder cancer has proven to be difficult on a population level, and our work may be a first step in identifying molecular markers for potential genetic-based screening tests. This will help recognize specific groups at increased risk beyond the existing known risk factors such as smoking and chemical exposure," said Dr. Lee.
Dr. Lee and his team also revealed that in patients with non-muscle invasive bladder cancer, 11 variants were linked with recurrence and 13 variants were linked with progression. Ten were associated with earlier death in patients with muscle invasive bladder cancer; rs2344673 was the most significant, with an average survival of 13.3 months in patients with the variant compared with 81.9 months in patients without it.
In the current era of personalized medicine, an individual's genetic information can provide valuable information on screening, treatment, and surveillance. "Our study provides an initial step in how we can use a patient's genetic makeup to identify those at risk for bladder cancer. Furthermore, we can identify patients who already have a diagnosis of bladder cancer that are at increased risk of worsening of disease or dying from their cancer," said Dr. Lee. "The goal is to find as many genetic alterations that confer risk and create a panel of markers that would aid in diagnosis, treatment, and follow- up."
###
URL Upon publication: http://doi.wiley.com/10.1002/cncr.27871
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
0The area around Berezovsky's house in Ascot, Berkshire, has been cordoned off to allow the investigation to take place.
0The news from Britain first emerged on Facebook, where Berezovsky?s son-in-law Egor Schuppe posted a status, giving no details regarding the nature of his death.
0Russian Channel One reports, the body of Russian tycoon, in early 1990?s member of Boris Yeltsin?s inner circle or "family" and then harsh critic of Vladimir Putin, was found in the bathroom of his Surrey estate.
0The channel also reported that Berezovsky suffered several heart attacks over the course of last week.
0Damian Kudriavtsev, the former CEO of Kommersant Publishing House also commented on the businessman?s death saying he passed away at 11:00 GMT in London. On his twitter account, Kudriavtsev said there were no signs of a violent death.
0"I can confirm he died in his home. I've known him for a long, long time, we have spent a lot of time together. I am shocked. It is the end of an epoch," Andrei Sidelnikov, who was a friend of Berezovsky's, told Reuters.
0"Yes, he is dead. It was confirmed to me by his private lawyer this afternoon," his spokesperson, Tim Bell, told news agency AFP.
Israel said it fired into Syria on Sunday and destroyed a machinegun position in the Golan Heights from where shots had been fired at Israeli soldiers in a further spillover of the Syrian civil war along a tense front.
It was not immediately clear whether Israel held Syrian troops or rebels responsible for what a spokesman for Prime Minister Benjamin Netanyahu said had been a deliberate attack on Israeli patrols in the occupied territory.
Israeli forces ?destroyed a Syrian machine gun nest that fired twice in the last 24 hours on Israeli patrols operating to safeguard the border,? the spokesman, Ofir Gendelman, said on his Twitter page.
Read full article
This article was posted: Sunday, March 24, 2013 at 11:03 am
The Samsung Galaxy S3 Mini hasn't exactly set the world alight, but Samsung looks set to continue the "Mini" line of devices with a new entrant later this year. The Samsung GT-i9190 -- rumored to go by the name of Galaxy S4 Mini -- has appeared online via the Twitter account a fellow named Ermek Kubanychbekov. Ermek, it seems, is also lucky enough to be in possession of a Galaxy S4. The shots posted on Twitter show the "S4 Mini" from various angles, along with some comparison pictures next to the Galaxy S3 and S4.
Physically, it's the spitting image of the Galaxy S4, right down to the patterned back cover and flattened sides.
On the software side the GT-i9190 is running what looks to be TouchWid'z Android 4.2.2 Jelly Bean, just like the full-sized S4. Specs, however seem to fall a little further down the food chain. The device is rumored to pack a 1.6GHz dual-core CPU with a 4.3-inch qHD (960x540) SuperAMOLED display.
Samsung has a track record of shipping many, many devices in the mid-range space, but it's interesting to see it once again breaking out its top-shelf branding for what might be a relatively humdrum phone. That said, we'll wait for more official info before passing judgment.
Mar. 22, 2013 ? Recent research in laboratory medicine has revealed crucial differences between men and women with regard to cardiovascular illness, cancer, liver disease, osteoporosis, and in the area of pharmacology.
At the dawn of the third millennium medical researchers still know very little about gender-specific differences in illness, particularly when it comes to disease symptoms, influencing social and psychological factors, and the ramifications of these differences for treatment and prevention. Medical research conducted over the past 40 years has focused almost exclusively on male patients.
A new article titled "Gender medicine: a task for the third millennium" presents research on gender-related differences conducted by Giovannella Baggio of Padua University Hospital and her team.
The article, which appears in the journal Clinical Chemistry and Laboratory Medicine (CCLM), highlights evidence for considerable differences between the sexes in five domains -- cardiovascular disease, cancer, liver diseases, osteoporosis, and pharmacology.
Typically perceived as a male illness, cardiovascular disease often displays markedly different symptoms among women. While a constricted chest and pain that radiates through the left arm are standard signs of heart attack in men, in women the usual symptoms are nausea and lower abdominal pain. Although heart attacks in women are more severe and complicated, when complaining of these non-specific symptoms women often do not receive the necessary examination procedures, such as an ECG , enzyme diagnostic tests or coronary angiography.
Colon cancer is the second most common form of cancer among men and women. However, women suffer this illness at a later stage in life. Furthermore, colon tumors typically have a different location in women, and they respond better to specific chemical treatments. Gender also has an impact on the patient's responsiveness to chemotherapy administered to treat cancer, such as colon, lung, or skin cancer. In this way, gender impacts the course of the disease and the patient's chances for survival.
Primary biliary cirrhosis is a liver disease that primarily affects women. The authors of the study provide clear evidence that for this disease and chronic hepatitis C, the genetic makeup and differing hormone levels of females are a primary risk factor. This finding also applies to osteoporosis. While typically viewed as a female disease because of the much higher rate of female patients, osteoporosis also strikes men. The study contends that osteoporosis is too often overlooked in male patients, and it documents a higher mortality rate among men suffering bone fractures.
Baggio and her team also show variation between men and women in the pharmacology of aspirin and other substances. Differences in action and side effects are attributable to different body types, varying reaction times in the absorption and elimination of substances, and a fundamentally different hormonal status. Thus, to administer medication safely and effectively, the dosage and duration of treatment must take the patient's gender into account.
The study concludes that additional and more far-reaching clinical investigations of gender differences are needed in order to eliminate fundamental inequalities between men and women in the treatment of disease.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by De Gruyter, via AlphaGalileo.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
Giovannella Baggio, Alberto Corsini, Annarosa Floreani, Sandro Giannini, Vittorina Zagonel. Gender medicine: a task for the third millennium. Clinical Chemistry and Laboratory Medicine, 2013; 0 (0): 1 DOI: 10.1515/cclm-2012-0849
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.